You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

Melanoma/Skin Cancer Trials

Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.

Page 1 of 1 | Results 1 - 5 of 5

A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma

The purpose of this study is to compare overall survival for patients receiving ipilimumab plus bevacizumab versus ipilimumab alone
John McCann, MD
Cancer, Cancer - Melanoma

D’Amour Center for Cancer Care
3350 Main Street
Springfield MA 01199

And

Franklin Medical Center
164 High Street
Greenfield, MA

 

NCI/CIRB EAY131 Molecular Analysis for Therapy Choice (MATCH)

John McCann, MD
Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate

D'Amour Center For Cancer Care

3350 Main Street
Springfield, MA 01199

NCI/CIRB S1609 DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS

John McCann, MD
Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate

D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199

Baystate Franklin Medical Center
164 High Street
Greenfield, MA 01301

Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

The purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab.  In this study, you will get either MK-3475 or a choice of either interferon alfa-2b or ipilimumab. 

John McCann, MD
Cancer - Melanoma

D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199

Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab

The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together. We would also like to find out what effects, good and bad, that this combination of drugs may have on your cancer.
John McCann, MD
Cancer - Melanoma, Cancer

D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199

Page 1 of 1 | Results 1 - 5 of 5